Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression

Table 1

Patient characteristics at the initiation of sorafenib treatment.

Characteristics
Sex
Male/female	54/17
Median age (years)	74 (48–88)
Cause
HCV/HBV/others	48/8/15
TNM stage
II/III/IVa/IVb	3/39/15/14
BCLC stage
B/C	41/30
Child-Pugh class
A/B/NA	59/11/1
Macrovascular invasion
Yes/no	17/54
Extrahepatic metastasis
Yes/no	14/57
ALT (U/L)^†	37 (9–119)
AST (U/L)^†	59 (14–268)
Total bilirubin (mg/dL)^†	0.9 (0.5–2.6)
Albumin (g/dL)^†	3.7 (2.4–4.9)
AFP (ng/mL)^†	171 (2–589,420)
DCP (mAU/mL)^†	313 (19–366,930)

The Child-Pugh status of one patient could not be classified because of warfarin usage for cardiovascular disease. ^†Data are the median values. HCV: hepatitis C virus; HBV: hepatitis B virus; BCLC; Barcelona clinic liver cancer; ALT: alanine aminotransferase; AST: aspartate aminotransferase; AFP: alpha-fetoprotein; DCP: des-gamma carboxy-prothrombin.